Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
金曜日, 9 04

Gilead Sciences Inc

GILDNASDAQ
Trade with Public
Trade with Public
$151.22
1.611.08%
近くで: Sep 2, 5:00 PM EST
$150.73
1.120.75%
プレマーケット: 6:27 AM EST
配当金: 配当落ち日は11 日後です。
概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

Gilead Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Gilead Sciences (GILD).

Price Target Range — 8 Quarters

Analyst Consensus — 23 Analysts

19Buy
4Hold
Consensus RatingBuy# Analysts23Avg. Consensus PT$135Upside to Avg. PT-10.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 5, 2026RBC CapitalBrian AbrahamsPT RaiseSector Perform$120→$123
Aug 5, 2026Cantor FitzgeraldCarter GouldMaintainedOverweight$155
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
CNBC Halftime Report Final Trades: Airbnb, Gilead Sciences, KLA, Snowflake

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $120 to $123.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price Target

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains $170 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $145

Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price target from $155 to $145.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $165

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $166 to $165.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved